Suscribirse

Characterization of high-grade prostate cancer at multiparametric MRI using a radiomic-based computer-aided diagnosis system as standalone and second reader - 28/09/23

Doi : 10.1016/j.diii.2023.04.006 
Tristan Jaouen a, Rémi Souchon a, Paul C Moldovan b, Flavie Bratan c, Audrey Duran d, Au Hoang-Dinh a, e, Florian Di Franco b, Sabine Debeer b, Marine Dubreuil-Chambardel b, Nicolas Arfi f, Alain Ruffion g, h, i, j, k, Marc Colombel i, j, l, m, Sébastien Crouzet a, i, j, l, m, Christelle Gonindard-Melodelima n, o, Olivier Rouvière a, b, i, j, m,
a INSERM, LabTAU, U1032, Lyon, 69003, France 
b Hospices Civils de Lyon, Hôpital Edouard Herriot, Department of Vascular and Urinary Imaging, Lyon, 69003, France 
c Hôpital Saint Joseph Saint Luc, Department of Radiology, Lyon, 69007, France 
d Univ Lyon, CNRS, Inserm, INSA Lyon, UCBL, CREATIS, UMR5220, U1294, Villeurbanne, 69100, France 
e Hanoi Medical University, Department of Radiology, Hanoi, 116001, Vietnam 
f Hôpital Saint Joseph Saint Luc, Department of Urology, Lyon, 69007, France 
g Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Department of Urology, Pierre-Bénite, 69310, France 
h Equipe 2 - Centre d'Innovation en Cancérologie de Lyon (EA 3738 CICLY), Pierre-Bénite, 69310, France 
i Université de Lyon, Lyon, 69003, France 
j Université Lyon 1, Lyon, 69003, France 
k Faculté de Médecine Lyon Sud, Pierre-Bénite, 69310, France 
l Hospices Civils de Lyon, Hôpital Edouard Herriot, Department of Urology, Lyon, 69003, France 
m Faculté de Médecine Lyon Est, Lyon, 69003, France 
n Université Grenoble Alpes, Laboratoire d'Ecologie Alpine, BP 53, Grenoble 38041, France 
o CNRS, UMR 5553, BP 53, Grenoble, 38041, France 

Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Highlights

In the peripheral zone, the best model for characterizing ISUP≥2 prostate cancer is a combination of 2nd ADC percentile and normalized wash-in rate.
In the transition zone, the best model for characterizing ISUP≥2 prostate cancer uses the 25th ADC percentile.
The zone-specific computer-aided diagnosis system combining the two best models provides diagnostic performance similar to that of PI-RADSv2 score in an internal and an external test dataset.
The CAD score threshold yielding 90% sensitivity at training shows a sensitivity close to 90% in both internal and external test datasets.

El texto completo de este artículo está disponible en PDF.

Abstract

Purpose

The purpose of this study was to develop and test across various scanners a zone-specific region-of-interest (ROI)-based computer-aided diagnosis system (CAD) aimed at characterizing, on MRI, International Society of Urological Pathology (ISUP) grade≥2 prostate cancers.

Materials and methods

ROI-based quantitative models were selected in multi-vendor training (265 pre-prostatectomy MRIs) and pre-test (112 pre-biopsy MRIs) datasets. The best peripheral and transition zone models were combined and retrospectively assessed in internal (158 pre-biopsy MRIs) and external (104 pre-biopsy MRIs) test datasets. Two radiologists (R1/R2) retrospectively delineated the lesions targeted at biopsy in test datasets. The CAD area under the receiver operating characteristic curve (AUC) for characterizing ISUP≥2 cancers was compared to that of the Prostate Imaging-Reporting and Data System version2 (PI-RADSv2) score prospectively assigned to targeted lesions.

Results

The best models used the 25th apparent diffusion coefficient (ADC) percentile in transition zone and the 2nd ADC percentile and normalized wash-in rate in peripheral zone. The PI-RADSv2 AUCs were 82% (95% confidence interval [CI]: 74–87) and 86% (95% CI: 81–91) in the internal and external test datasets respectively. They were not different from the CAD AUCs obtained with R1 and R2 delineations, in the internal (82% [95% CI: 76–89], P = 0.95 and 85% [95% CI: 78–91], P = 0.55) and external (82% [95% CI: 74–91], P = 0.41 and 86% [95% CI:78–95], P = 0.98) test datasets. The CAD yielded sensitivities of 86–89% and 90–91%, and specificities of 64–65% and 69–75% in the internal and external test datasets respectively.

Conclusion

The CAD performance for characterizing ISUP grade≥2 prostate cancers on MRI is not different from that of PI-RADSv2 score across two test datasets.

El texto completo de este artículo está disponible en PDF.

Key words : Artificial intelligence, Computer-assisted diagnosis, Magnetic resonance imaging, Prostatic neoplasms, Validation study

Abbreviations : ADC, ADC2, ADC25, AUC, CAD, CI, DCE, ISUP, mpMRI, PI-RADSv2, PZ, ROI, TZ, WI


Esquema


© 2023  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 104 - N° 10

P. 465-476 - octobre 2023 Regresar al número
Artículo precedente Artículo precedente
  • Modified Appleby procedure for locally advanced pancreatic carcinoma: A primer for the radiologist
  • Rémy Sindayigaya, Maxime Barat, Stylianos Tzedakis, Raphael Dautry, Anthony Dohan, Arthur Belle, Romain Coriat, Philippe Soyer, David Fuks, Ugo Marchese
| Artículo siguiente Artículo siguiente
  • Detection of arterial phase hyperenhancement of small hepatocellular carcinoma with MRI: Comparison between single arterial and multi-arterial phases and between extracellular and hepatospecific contrast agents
  • Thomas Bouyer, Marine Roux, Sarah Jacquemin, Marco Dioguardi Burgio, Olivier Sutter, Valérie Laurent-Croisé, Julie Lonjon, Ivan Bricault, Hervé Trillaud, Agnès Rode, Christophe Aubé, Anita Paisant

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.